IceCure Ltd. (TASE: ICCM) has begun sales of its cryoablation IceSense3 product in the US, and the first four procedures in the US were carried out at Park Avenue Surgical Associates in Trumbull, Connecticut. The treatments will receive full insurance indemnification.
The IceSense3 is a minimally-invasive solution for in-office treatment of Fibroadenoma, or benign breast disease, which affects millions of women each year. The procedure uses a proprietary disposable needle to freeze, or cryoablate the benign tumors.
The procedures were carried out by Dr. Andrew Kenler, who has conducted more than 200 procedures to remove breast tumors by cryoablation. All four procedures were successful and completed within 4.5 minutes, a process that is much faster than other procedures.
IceCure's share price rose 5.3% today to NIS 7.43, giving a market cap of NIS 94 million.
Published by Globes [online], Israel business news - www.globes-online.com - on March 30, 2011
© Copyright of Globes Publisher Itonut (1983) Ltd. 2011